MeSH | Anemia, Aplastic (D000741)

Anemia, Aplastic D000741

Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Anemia » Anemia, Aplastic

Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Bone Marrow Diseases » Bone Marrow Failure Disorders » Anemia, Aplastic

Description

A form of anemia in which the bone marrow fails to produce adequate numbers of peripheral blood elements. MeSH

Hierarchy View

View MeSH Tree View ICD-10 Tree

Subtype Terms (1)

Anemia, Hypoplastic, Congenital
1 experimental drug

Approved Indicated Drugs (4)

eltrombopag (promacta)

prednisone (meticorten)

Phase 4 Indicated Drugs (13)

allogeneic cord blood

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)

busulfan (Myleran)

cyclophosphamide (cytoxan)

cyclosporine (sandimmune)

cytarabine (cytosar-u)

deferasirox (exjade)

fludarabine (fludara)

hetrombopag olamine

posaconazole (noxafil)

Phase 3 Indicated Drugs (9)

allogeneic bone marrow

antilymphocyte serum

heparin (liquaemin)

lymphocyte immune globulin, anti-thymocyte globulin (equine) (Atgam)

nandrolone phenpropionate (Durabolin)

prednisolone (hydeltra)

sargramostim (leukine)

sodium chloride

Phase 2 Indicated Drugs (36)

allogeneic hematopoietic stem cells (Hemacord)

allogeneic lymphocytes

allogeneic transplant donor lymphocytes, depleted of tcr-αβ t cells and b cells; enriched for nk cells and tcrγδ t cells

allogenic t cell-depleted hematopoietic stem cells

autologous hematopoietic stem cells

autologous mesenchymal stem cells

autologous umbilical cord blood

basiliximab (Simulect)

bone marrow derived mesenchymal stem cells

carmustine (bicnu)

cd45-depleted allogenic peripheral blood stem cell

clofarabine (clolar)

daclizumab (Zenapax)

decitabine (dacogen)

etoposide (vepesid)

Filgrastim (neupogen)

haploidentical mononuclear cells

hemopoietic stem cell

ibrutinib (imbruvica)

levamisole (ergamisol)

luspatercept (Reblozyl)

melphalan (alkeran)

mesna (mesnex)

mycophenolate (CellCept)

naltrexone (revia)

parathyroid hormone (Natpara)

peripheral blood lymphocytes

rituximab (rituxan)

sirolimus (rapamune)

tacrolimus (prograf)

t cell depleted hematopoietic stem cells

umbilical cord mesenchymal stem cells

Phase 1 Indicated Drugs (8)

abatacept (orencia)

aldhbr umbilical cord blood cells

alefacept (Amevive)

autologous regulatory t cells

daratumumab (darzalex)

donor memory t cells that have been depleted of cd62l+

human placental derived stem cells

Other Experimental Indicated Drugs (7)

allogeneic stem cells

autologous cd34+ cells

foscarnet (foscavir)

ganciclovir (cytovene)

interferon alpha-2b (Intron-A)

valganciclovir (Valcyte)

Organization Involved with Phase 4 Indications (24)

Assiut University

Chinese Academy of Medical Sciences

Guangzhou Medical University

Harbin Medical University

Huazhong University of Science and Technology

Jiangxi Provincial People's Hospital

Jiao Tong University

Jinhua Central Hospital

Jining NO.1 People 's Hospital

Linyi People's Hospital

Nanjing Medical University

People's Liberation Army of China

Qingdao Center Medical Group

Qingdao University

Shandong Cord Blood Bank

Shandong University of Traditional Chinese Medicine

Shengjing Hospital

Tai'an Central Hospital

University of Arizona

University of London

Weifang Medical University

Yishui Central Hospital of LINYI

Zhejiang Chinese Medical University

Organization Involved with Phase 3 Indications (21)

Dmitry Rogachev Federal Research and Clinical Centre of Paediatric Haematology, Oncology and Immunology

European Group for Blood and Marrow Transplantation

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Government of Japan

Hengrui Therapeutics, Inc.

Kyowa Hakko Kirin

Nagoya University

National Heart, Lung, and Blood Institute (NHLBI)

National Institutes of Health (NIH)

Paris Diderot University

State University of New York, Buffalo

University of Alberta

University of Bern

University of Calgary

University of Minnesota

University of Naples Frederico II

University of Ulm

University of Ulsan

Organization Involved with Phase 2 Indications (72)

Baylor University

Bellicum Pharmaceuticals

BioLineRx, Ltd.

Blood and Marrow Transplant Clinical Trials Network

Burnasyan Federal Medical Biophysical Center

Cellphire, Inc.

Center for International Blood and Marrow Transplant Research

Children's Hospital Los Angeles

China Medical University

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Cornell University

Department of Health and Human Services

Duke University

German Research Foundation

Government of China

Government of Korea

Government of Pakistan

Guangdong Prevention and Treatment Center for Occupational Diseases

Harvard University

Indiana University

Jinan University

Johns Hopkins University

Julius-Maximilians University

King Faisal Specialist Hospital

King Faisal University

Medical College of Wisconsin

Methodist Cancer Center, Houston, Texas

Miltenyi Biotec, Inc.

National Cancer Institute (NCI)

National Center for Research Resources (NCRR)

National Marrow Donor Program

New York Medical College

Northside Hospital, Inc.

Northwell Health

Ohio State University

Oregon Health and Science University

Peking University

Rockefeller University

Seoul National University

Shantou University

Southern Medical University

St. Jude Children's Hospital

Sun Yat-Sen University

Texas Oncology Cancer Center

The EMMES Corporation

The Korean Society of Pediatric Hematology Oncology

The Second People's Hospital of GuangDong Province

Thomas Jefferson University

Tianjin Medical University

Tsinghua University

Tufts University

University of Alabama, Birmingham

University of California, Los Angeles

University of California, San Diego

University of California, San Francisco

University of Chicago

University of Cincinnati

University of Duisburg-Essen

University of Erlangen-Nuremberg

University of Florida

University of Regensburg

University of Rochester

University of Sao Paulo

University of Southern California

University of Texas at Houston

University of Utah

University of Washington

University of Wisconsin

Organization Involved with Phase 1 Indications (11)

Case Western Reserve University

Emory University

Food and Drug Administration

Hebei University

Medical Research Council

Memorial Sloan-Kettering Cancer Center

New York Blood Center

University of Iowa

Organization Involved with Other Experimental Indications (6)

City of Hope National Medical Center

Columbia University

Northwestern University

Universidad Autonoma de Nuevo Leon

University of Illinois at Chicago

West Virginia University

Hierarchy Tree View

MeSH
ICD-10

UMLS Data

YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.